You eat less because you're not hungry
The medication's stability profile has been extensively studied, and degradation pathways generally result in inactive peptide fragments rather than harmful compounds
Combination with Other Compounds: Sometimes, researchers explore synergistic effects by combining 5-Amino-1MQ with other compounds
GLP-1-based compounds work primarily through appetite suppression, and the weight loss they produce includes significant lean mass loss (approximately 40% of total weight lost is lean tissue based on STEP trial data)
Assuming that the percentage of patients showing an increase in serum vitamin B12 concentration to above 179 pg/ml in both groups is 70%, means the study requires at least 304 patients (152 in each arm) for a threshold of non-inferiority of 10% and a statistical power of 60% with significance set at p 179 pg/ml: patient preference questionnaire Randomisation of patients to treatment group Visit 1 (start of treatment) Anamnesis: record whether the patient lives alone or with others, lifestyle habits, use of alcohol, whether a vegan diet is followed, whether the patient has undergone gastrectomy Symptoms: record paresthesia, asthenia, loss or reduction of appetite, sadness or change in state of mind, concomitant pharmacological treatment Physical examination: for Hunters glositis, positional and vibrational sensitivity Questionnaires: Lobo cognitive mini-exam, EuroQoL-5D Record concomitant treatment Request analyses to be performed one week before next visit: haemogram and serum vitamin B12 Therapeutic plan: patient in oral arm provision of medication
